Our mission is to provide the “gold-standard” collection of well-characterised models and services for drug discovery to help our clients reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic.
Crown Bioscience, Inc. is a Preclinical CRO with expertise in the disease areas of Oncology and Metabolic Disease . We are known for the breadth and quality of our in vitro and in vivo models, as well as our ability to help clients quantify the real efficacy and pharmacological profile of their candidate before they move into the clinic. www.crownbio.com
The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute-designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for immuno-oncology drug development. www.jax.org
MI Bioresearch (MI), a preclinical oncology service provider, offers in vitro services, oncology pharmacology, in vivo imaging, and focal radiation to support research programs. Our team explores the effects of your drugs and biologics using both human and syngeneic models and multi-modality imaging systems. MI provides you with decision-driving data to help advance your drug candidate toward the next cancer research breakthrough. One Focus. One Purpose. Oncology Research.
Pharmatest Services Ltd is a CRO offering preclinical efficacy services for the pharmaceutical industry. We offer bothin vitro and in vivo models in the fields of oncology and skeletal diseases. In oncology we have special expertise in clinically predictive orthotopic and metastasis models, and especially models of bone metastasis.
VisualSonics is the world’s leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company’s enabling technology allows researchers at the world’s most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research in cardiovascular, cancer, and developmental biology areas. The technology supports applications that include genetic research, phenotypic studies and drug development.
ANGLE’s Parsortix technology enables the capture and harvest of circulating tumor cells from patient blood. The resulting liquid biopsy (simple blood test) provides a powerful tool to deliver personalized cancer care. ANGLE is currently developing its first diagnostic product in the area of ovarian cancer. The Parsortix system has CE Mark regulatory approval in Europe and an FDA approval process is underway in the US.